Upcoming webinar
Chronic pain remains a significant and multifaceted challenge for patients and healthcare systems worldwide, driving growing interest in innovative, mechanism-based treatment approaches.
European evidence-based guidelines on rTMS, including the IFCN/European expert consensus (Lefaucheur et al. 2014; 2020 update), now incorporate pain management and identify the primary motor cortex (M1) as a key target for neuromodulation. These guidelines report Level A evidence for high-frequency M1 rTMS in neuropathic pain and Level B evidence in fibromyalgia, highlighting increasing clinical and scientific focus on cortical pain modulation.
More recently, M1 rTMS has been incorporated into the 2025 neuropathic pain guidelines. It is currently the only non-invasive neuromodulation modality that is both approved and recommended. This progress aligns with ongoing research from leading centers such as the Center for Neuroplasticity and Pain at Aalborg University, where Daniel Ciampi de Andrade and colleagues contribute to the expanding evidence base supporting M1 rTMS within clinical guidance.
Join us for this educational webinar where Daniel Ciampi de Andrade, MD, PhD, neurologist and professor at Aalborg University will provide an overview of this recent update to the guidelines and explore in more detail the role of M1 and rTMS in chronic pain management.
Professor Daniel Ciampi de Andrade, MD, PhD
Neurologist, Professor, Center for Neuroplasticity and Pain, Faculty of Medicine, Aalborg University, Denmark